Retinoschisis Pipeline Analysis report covers 2 drugs currently in different phases of development. Retinoschisis is an ophthalmic condition where part of retina is split into two layers. The split part of retina is characterised by suboptimal vision. The retinoschisis may be classified into two types: Genetic Juvenile X-linked Retinoschisis and acquired Degenerative retinoschisis. Symptoms of retinoschisis are decreased central and peripheral vision. An electroretinogram is done to diagnose retinoschisis.
The report provides retinoschisis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Adverum Biotechnologies, Applied Genetic Technologies Corporation.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration